Chinese Radiology Imaging Firm Nanovision Technology Closes on Nearly $23M Series B Round

According to VCBeat, Nanovision Technology, a high-tech enterprise focused on high-speed and high-precision radiology imaging, has raised 160 million yuan (US$22.93 million) in its Series B round of financing led by Sherpa Venture Capital. Li Yunxiang, CEO of Nanovision Technology, said, "Proceeds of this round will be used for the commercialization of the product." 

Nanovision Technology is located in Zhongguancun Yongfeng high-tech industrial base, with thousands of square meters of R&D foundation in Yonyou Industrial Park. It has also set up a subsidiary company in Chengdu. Nanovision Technology focuses on static CT，X-ray CMOS detectors and X-ray imaging software, etc., which can be widely used in medical, industrial, security and other fields.

In the 105th session of the radiological society of North America (RSNA), Nanovision Technology team showed the prototype model of its static CT and got attention from many famous institutions and people, among whom also expressed willingness of cooperation.

Nanovision Technology has raised a total of 300 million yuan including the latest round, from investors such as Legend Capital, Sherpa Capital, and Hillhouse Capital.

Cai Daqing, Sherpa Venture Capital's founding partner, once said: "There is a CT company whose machines can improve spatial resolution by four times and temporal resolution by 10 times. This is a huge selling point. In the future, it's possible to look at images of the heart by the way of high-speed photography, and which muscles are weak and unable to contract because of blocked blood vessels, can be clearly presented to the cardiologist." Nanovision Technology is just this CT company.

Founded in 2018 and is headquartered in Beijing, China, Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where the company has established robust portfolio sources, lasting value-adding cooperation and relationships, as well as mature all-cycle services with key resources.